In the BioHarmony Drug Report Database
Flibanserin
Addyi (flibanserin) is a small molecule pharmaceutical. Flibanserin was first approved as Addyi on 2015-08-18. The pharmaceutical is active against 5-hydroxytryptamine receptor 1A and 5-hydroxytryptamine receptor 2A. Addyi’s patents are valid until 2023-05-09 (FDA).
Trade Name
|
Addyi |
|---|---|
Common Name
|
flibanserin |
ChEMBL ID
|
CHEMBL231068 |
Indication
|
|
Drug Class
|
Serotonin 5-HT2 receptor antagonists |
Image (chem structure or protein)